Trial | NCT02129673  Report issue

Title

A Phase 1/2 Multicenter, Randomized, Study to Evaluate the Safety and Efficacy of VS101 Subconjunctival Latanoprost Insert in Subjects With Open-Angle Glaucoma or Ocular Hypertension
A Phase 1/2 Multicenter, Randomized, Controlled Dose-Finding Study to Evaluate the Safety and Ocular Hypotensive Efficacy of 3 Dose Levels of the VS101 Subconjunctival Latanoprost Insert for 3 Months in Subjects With Open-Angle Glaucoma or Ocular Hypertension

  • Phase

    Phase 1/Phase 2

  • Study Type

    Interventional

  • Status

    Completed No Results Posted

  • Intervention/Treatment

    latanoprost ...

  • Study Participants

    77
Slow release formulation of latanoprost is compared for safety and pressure-lowering efficacy with topically administration of commercially available latanoprost in patient with glaucoma and ocular hypertension
Study Started
May 31
2014
Primary Completion
May 31
2017
Study Completion
Aug 31
2017
Last Update
Mar 14
2018

Drug VS101 Insert Dose A

Sustained release of latanoprost into the eye

Drug VS101 Insert Dose B

Sustained release of latanoprost into the eye

Drug VS101 Insert Dose C

Sustained release of latanoprost into the eye

Drug Latanoprost 0.005% eye drops

Latanoprost 0.005% eye drops administered once daily on the eye

VS101 Insert Dose A Experimental

VS101 Insert Dose A placed under the conjunctiva

VS101 Insert Dose B Experimental

VS101 Insert Dose B placed under the conjunctiva

VS101 Insert Dose C Experimental

VS101 Insert Dose C placed under the conjunctiva

Latanoprost 0.005% eye drops Active Comparator

Latanoprost 0.005% eye drops administered once daily on the eye

Criteria 

Inclusion Criteria:

Age > 18
Open angle glaucoma or Ocular Hypertension

Exclusion Criteria:

uncontrolled medical conditions
wearing of contact lenses
No Results Posted